Please login to the form below

Not currently logged in
Email:
Password:

roxadustat

This page shows the latest roxadustat news and features for those working in and with pharma, biotech and healthcare.

GSK files anaemia drug daprodustat in Japan, its first market

GSK files anaemia drug daprodustat in Japan, its first market

Another oral HIF-PHI drug – AstraZeneca and FibroGen’s  roxadustat– has already been approved in China for CKD anaemia.Additional competition could come from Akebia, which has a drug in the ... Astellas Pharma meanwhile has rights to roxadustat in

Latest news

  • AZ preps new roxadustat filings, though data foxes investors AZ preps new roxadustat filings, though data foxes investors

    Comes with increased blood pressure warning label. AstraZeneca and FibroGen say they are preparing a US filing of roxadustat for anaemia in chronic kidney disease after reporting cardiovascular outcomes data from ... There is a significant unmet medical

  • First-line ovarian approval cements AZ’s Lynparza lead First-line ovarian approval cements AZ’s Lynparza lead

    And in another positive development, AZ also announced today that two additional phase 3 trials of its just-approved drug for anaemia in chronic kidney disease patients – roxadustat – backed the efficacy

  • China first market to approve AZ’s kidney drug roxadustat China first market to approve AZ’s kidney drug roxadustat

    Roxadustat was compared to treatment with epoetin alfa over 26 weeks, matching the ESA’s efficacy in achieving a significant increase in haemoglobin levels. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while

  • AZ, FibroGen's anaemia drug on course for first filing this year AZ, FibroGen's anaemia drug on course for first filing this year

    Roxadustat works by turning on the body's machinery for producing red blood cells that is usually stimulated by reduced oxygen levels in the blood. ... In addition, use of roxadustat is free of the burden of cold-chain storage and maintaining sterility,

  • GSK starts late-stage trials of daprodustat GSK starts late-stage trials of daprodustat

    administration.". GSK is in a race to market with other HIF-PHI developers, including FibroGen, which has a candidate called roxadustat (FG-4592) in late-stage trials in China for anaemia ... FibroGen said recently it is on track to file a marketing

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics